ATE106249T1 - Polysaccharidmodifizierte immunglobuline mit reduziertem immunogenem potential oder verbesserter pharmakokinetik. - Google Patents

Polysaccharidmodifizierte immunglobuline mit reduziertem immunogenem potential oder verbesserter pharmakokinetik.

Info

Publication number
ATE106249T1
ATE106249T1 AT88310372T AT88310372T ATE106249T1 AT E106249 T1 ATE106249 T1 AT E106249T1 AT 88310372 T AT88310372 T AT 88310372T AT 88310372 T AT88310372 T AT 88310372T AT E106249 T1 ATE106249 T1 AT E106249T1
Authority
AT
Austria
Prior art keywords
immunogenic potential
immunoglobulin
improved pharmacokinetics
modified immunoglobulins
reduced immunogenic
Prior art date
Application number
AT88310372T
Other languages
English (en)
Inventor
Roberto Cesare Fagnani
Original Assignee
Hybritech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybritech Inc filed Critical Hybritech Inc
Application granted granted Critical
Publication of ATE106249T1 publication Critical patent/ATE106249T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT88310372T 1987-11-05 1988-11-03 Polysaccharidmodifizierte immunglobuline mit reduziertem immunogenem potential oder verbesserter pharmakokinetik. ATE106249T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11815087A 1987-11-05 1987-11-05

Publications (1)

Publication Number Publication Date
ATE106249T1 true ATE106249T1 (de) 1994-06-15

Family

ID=22376776

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88310372T ATE106249T1 (de) 1987-11-05 1988-11-03 Polysaccharidmodifizierte immunglobuline mit reduziertem immunogenem potential oder verbesserter pharmakokinetik.

Country Status (5)

Country Link
EP (1) EP0315456B1 (de)
JP (1) JPH01163133A (de)
AT (1) ATE106249T1 (de)
AU (1) AU610946B2 (de)
DE (1) DE3889853D1 (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5541297A (en) * 1988-04-01 1996-07-30 Immunomedics, Inc. Therapeutic conjugates of toxins and drugs
US8038994B2 (en) 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
US5929049A (en) 1997-08-08 1999-07-27 Dade Behring Marburg Gmbh Polysaccharide conjugates of biomolecules
DK2319928T3 (da) 1998-10-23 2013-06-24 Kirin Amgen Inc Dimere trombopoietiske peptidomimetika, der binder til MPL-receptor og har trombopoietisk aktivitet
US6245879B1 (en) * 1999-01-29 2001-06-12 Shell Oil Company Purification of 1,3-propanediol in carbonyl-containing stream
US7871597B2 (en) 1999-04-09 2011-01-18 Amag Pharmaceuticals, Inc. Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
ITMI20010347A1 (it) * 2001-02-21 2002-08-21 Grisotech S A Complessi di immunoglobuline e polisaccaridi per assorbimento orale etrans-mucosale
JP4516719B2 (ja) 2001-05-11 2010-08-04 アムジエン・インコーポレーテツド Ｔａｌｌ−１と結合するペプチド及び関連分子
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US20040136992A1 (en) 2002-08-28 2004-07-15 Burton Paul B. J. Compositions and method for treating cardiovascular disease
EP1648935A2 (de) 2003-07-25 2006-04-26 Amgen Inc. Antagonisten und agonisten von ldcam und anwendungsverfahren
DK2311873T3 (en) 2004-01-07 2018-11-26 Novartis Vaccines & Diagnostics Inc M-CSF-SPECIFIC MONOCLONAL ANTIBODY AND APPLICATIONS THEREOF
CA2572765C (en) 2004-07-08 2013-05-21 Amgen Inc. Compound having improved bioefficiency when administered in a multidose regimen
CN101103045B (zh) 2004-09-24 2015-11-25 安姆根有限公司 修饰的Fc分子
CA2589860A1 (en) 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
JP5457671B2 (ja) 2005-07-28 2014-04-02 ノバルティス アーゲー Ｍ−ｃｓｆ特異的モノクローナル抗体およびその使用
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
NZ597082A (en) 2005-10-13 2013-11-29 Human Genome Sciences Inc Methods and Compositions for Use in Treatment of Patients with Autoantibody Positive Diseases
PE20070684A1 (es) 2005-11-14 2007-08-06 Amgen Inc MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP
US8278421B2 (en) 2006-03-20 2012-10-02 Xoma Techolology Ltd. Human antibodies specific for gastrin materials and methods
JO3324B1 (ar) 2006-04-21 2019-03-13 Amgen Inc مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
TWI395754B (zh) 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
RU2008150314A (ru) 2006-05-19 2010-06-27 Гликофи, Инк. (Us) Композиции эритропоэтина
US7981425B2 (en) 2006-06-19 2011-07-19 Amgen Inc. Thrombopoietic compounds
ES2376396T3 (es) 2006-06-26 2012-03-13 Amgen Inc. Método para tratar aterosclerosis.
EP2057193B1 (de) 2006-08-04 2013-12-18 Novartis AG Ephb3-spezifischer antikörper und verwendungen davon
HRP20140081T1 (hr) 2006-08-18 2014-03-28 Novartis Ag Prlr-specifiäśna antitijela i njihova uporaba
PE20081140A1 (es) 2006-10-25 2008-09-22 Amgen Inc Agentes terapeuticos a base de peptidos derivados de toxinas
CA2672120A1 (en) 2006-12-07 2008-06-12 Novartis Ag Antagonistic antibodies against ephb3
JP5591691B2 (ja) 2007-05-22 2014-09-17 アムジエン・インコーポレーテツド 生物活性を有する融合タンパク質を作製するための組成物及び方法
MY159075A (en) 2007-07-26 2016-12-15 Amgen Inc Modified lecithin-cholesterol acyltransferase enzymes
EP2261254A3 (de) 2007-12-21 2011-04-13 Amgen, Inc Antiamyloide Antikörper und deren Verwendungen
CA2711826C (en) 2008-01-25 2018-02-27 Amgen Inc. Ferroportin antibodies and methods of use
US9315577B2 (en) 2008-05-01 2016-04-19 Amgen Inc. Anti-hepcidin antibodies and methods of use
EA024751B8 (ru) 2008-06-04 2020-01-31 Амген Инк. Мутанты fgf21 и их применение
EP2307456B1 (de) 2008-06-27 2014-10-15 Amgen Inc. Die inhibierung von ang-2 zur behandlung multipler sklerose
EP2358749B1 (de) 2008-10-10 2018-07-18 Amgen, Inc Fgf21-mutanten und ihre verwendungen
US8143347B2 (en) 2008-10-15 2012-03-27 Baxter International Inc. Pegylation of recombinant blood coagulation factors in the presence of bound antibodies
WO2010108154A2 (en) 2009-03-20 2010-09-23 Amgen Inc. Selective and potent peptide inhibitors of kv1.3
US20120052069A1 (en) 2009-05-05 2012-03-01 Amgen Inc Fgf21 mutants and uses thereof
SMT202400036T1 (it) 2009-05-05 2024-03-13 Amgen Inc Mutanti fgf21 e loro utilizzi
AU2010262927A1 (en) 2009-06-17 2012-01-19 Amgen Inc. Chimeric FGF19 polypeptides and uses thereof
JP2012530498A (ja) 2009-06-19 2012-12-06 メディミューン，エルエルシー プロテアーゼバリアント
AU2010298036B2 (en) 2009-09-25 2015-05-21 Xoma Technology Ltd. Screening methods
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
US20120231006A1 (en) 2009-11-20 2012-09-13 Amgen Inc. Anti-orai1 antigen binding proteins and uses thereof
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
US9517264B2 (en) 2010-04-15 2016-12-13 Amgen Inc. Human FGF receptor and β-Klotho binding proteins
CN103339145A (zh) 2010-09-22 2013-10-02 安姆根有限公司 运载体免疫球蛋白及其用途
US9023791B2 (en) 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
EP3954704A1 (de) 2011-06-03 2022-02-16 XOMA Technology Ltd. Tgf-beta-spezifische antikörper
CA2845357A1 (en) 2011-08-31 2013-03-07 Amgen Inc. Method of treating or ameliorating type 1 diabetes using fgf21
UY34346A (es) 2011-09-26 2013-04-30 Novartis Ag Proteínas de fusión para tratar trastornos metabólicos
UY34347A (es) 2011-09-26 2013-04-30 Novartis Ag Proteínas de función dual para tratar trastornos metabólicos
KR102218494B1 (ko) 2013-03-15 2021-02-19 인트린식 라이프사이언시스, 엘엘씨 항-헵시딘 항체 및 그의 용도
US20160235810A1 (en) 2013-10-18 2016-08-18 Novartis Ag Methods of treating diabetes and related disorders
AU2015321462B2 (en) 2014-09-22 2020-04-30 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
JP2018529729A (ja) 2015-10-01 2018-10-11 アムジエン・インコーポレーテツド 胆汁酸障害の処置
SG10202001787QA (en) 2016-06-02 2020-04-29 Abbvie Inc Glucocorticoid receptor agonist and immunoconjugates thereof
CA3082356A1 (en) 2017-12-01 2019-06-06 Abbvie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof
JP7607579B2 (ja) 2019-03-27 2024-12-27 ティガティーエックス， インコーポレイテッド 工学的に操作されたＩｇＡ抗体および使用方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1541436A (en) * 1976-02-02 1979-02-28 Searle & Co Immunological materials
NZ214503A (en) * 1984-12-20 1990-02-26 Merck & Co Inc Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates
US4732863A (en) * 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
US4699784A (en) * 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate

Also Published As

Publication number Publication date
DE3889853D1 (de) 1994-07-07
JPH01163133A (ja) 1989-06-27
EP0315456B1 (de) 1994-06-01
AU2475588A (en) 1989-05-18
EP0315456A2 (de) 1989-05-10
AU610946B2 (en) 1991-05-30
EP0315456A3 (en) 1990-03-28

Similar Documents

Publication Publication Date Title
ATE106249T1 (de) Polysaccharidmodifizierte immunglobuline mit reduziertem immunogenem potential oder verbesserter pharmakokinetik.
Davis et al. A simple modified carbodiimide method for conjugation of small-molecular-weight compounds to immunoglobulin G with minimal protein crosslinking
EP0527821A4 (en) Oxidation resistant thrombomodulin analogs
ATE108799T1 (de) Konjugate von in position c-3 eine detergens- kette enthaltenden vinca-derivaten.
DE69333107T2 (de) Dualer träger für immunogene konstrukte
DE69127523D1 (de) Polymermischung
FI913169A0 (fi) Oligonukleotidanaloger med terminala 3'-3'- eller 5'-5'-internukleotidkopplingar.
FI903464A0 (fi) Foerfarande foer oxiderande denaturering av proteinanalyter.
ATE259878T1 (de) Verfahren zur verbesserung der immunogenität einer immunogenen zusammensetzung oder eines haptens und verwendung zur herstellung von impfstoffen
DK526289D0 (da) Kosmetisk praeparat indeholdende chitosan
FR2522967B1 (fr) Conjugues d'haptenes et de muramyl-peptides, doues d'activite immunogene et compositions les contenant
DE69419966D1 (de) Impstoff gegen Streptococcus suis-Infektion
AU549495B2 (en) Immunoglobulin-vindesine conjugates
SE7608174L (sv) Forfarande for framstellning av antiserum
KR860003825A (ko) 안정한 현탁액 제조용 고체 약물제형의 제조방법
ATE168115T1 (de) In lösung bringen von proteinen in aktiver form
FI854511A0 (fi) Vattenloesliga polymerer.
DK0529019T3 (da) Nematodevaccine
SE8602523L (sv) 2-alkyl- eller -aralkyltio-1-cykloalken-1-karboxamider och deras sulfoxider, sett for deras framstellning och deras anvendning for syntes av tri- och 4,5-tetrametylen-4-isotiazolin-3-oner
PT91571A (pt) Verfahren fuer die herstellung von phyto und zoosterole und deren derivate mit verbesserter wasseroeslichkeit
DE3884315D1 (de) Verwendung von Epithioderivaten ungesättigter Kohlenstoffverbindungen als Weichmacher sowie diese enthaltende Dichtungsmassen.
SE8504228L (sv) Tumordodande emne
DE69128095D1 (de) Azelluläre impfstoffe

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties